VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KNSA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KNSAKiniksa Pharmaceuticals International, plc
$95.05$7.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. KNSA
  4. Financial Ratios

Kiniksa Pharmaceuticals International, plc (KNSA) Financial Ratios

Latest Ratios: P/E Ratio 73.7x · EV/EBITDA 53.5x · ROE 11.7%. (2016–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

KNSA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$7.2B$3.3B$1.4B$1.3B$1.1B$807M$1.1B$598M$830M——
Enterprise Value$7.1B$3.1B$1.2B$1.2B$938M$691M$986M$554M$523M——
P/E Ratio →73.6755.00—87.705.76——————
P/S Ratio7.664.813.344.674.7920.94—————
P/B Ratio13.235.743.222.872.664.363.502.65———
P/FCF36.73128.2055.5995.78185.01——————
P/OCF281.96126.8255.0094.84181.66——————

P/E links to full P/E history page with 30-year chart

KNSA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—4.582.934.314.2617.92—————
EV / EBITDA53.5439.38——77.05——————
EV / EBIT91.7834.90——85.08——————
EV / FCF—122.0648.7688.52164.52——————

KNSA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin54.6%54.6%85.6%79.1%89.6%76.4%—————
Operating Margin11.4%11.4%-10.8%-9.3%4.4%-406.4%—————
Net Profit Margin8.7%8.7%-10.2%5.2%83.3%-409.7%—————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE11.7%11.7%-9.8%3.4%63.1%-63.6%-60.1%-1037.7%———
ROA8.8%8.8%-7.8%2.9%53.0%-54.2%-53.4%-56.2%-55.9%-124.8%-42.5%
ROIC17.1%17.1%-11.3%-6.1%4.2%-85.9%-61.1%-70.4%———
ROCE14.0%14.0%-9.7%-5.8%3.3%-62.0%-57.8%-67.2%-69.9%-155.3%-44.3%

KNSA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.020.020.020.030.010.030.020.01———
Debt / EBITDA0.120.12——0.49——————
Net Debt / Equity—-0.28-0.40-0.22-0.29-0.63-0.34-0.20———
Net Debt / EBITDA-1.98-1.98——-9.59——————
Debt / FCF—-6.14-6.84-7.27-20.48——————
Interest Coverage———————————

Net cash position: cash ($166M) exceeds total debt ($9M)

KNSA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio3.793.793.304.345.164.3810.468.687.372.7024.47
Quick Ratio3.393.393.043.854.714.3010.468.687.372.7024.47
Cash Ratio2.982.982.423.244.054.0610.168.397.222.6124.31
Asset Turnover—0.890.730.510.480.17—————
Inventory Turnover5.605.602.311.821.062.48—————
Days Sales Outstanding—8.4035.9828.7233.6837.74—————

KNSA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield1.4%1.8%—1.1%17.4%——————
FCF Yield2.7%0.8%1.8%1.0%0.5%——————
Buyback Yield0.1%0.2%0.4%0.2%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.1%0.2%0.4%0.2%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$79M$71M$72M$70M$69M$62M$54M$30M$32M$32M

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Single-product dependency and margin ceiling

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Structural Margin Ceiling Offsets Operating Leverage

Kiniksa's operating margin expanded from -0.1% in 2024Q2 to 19.0% in 2026Q3, yet gross margin has settled near 53-55%, well below the 80-90% typical of asset-owning orphan drug companies, as reported in Kiniksa's quarterly filings, reflecting the Regeneron profit-share drag.

The decomposition is revealing: profitability improvement is coming almost entirely from operating leverage on SG&A rather than gross margin expansion, meaning each incremental ARCALYST dollar converts at a structurally lower rate than at peers who own their assets outright. Net margin of 16.6% in 2026Q3 sits below the 19.0% operating margin, suggesting below-the-line items — potentially collaboration expense allocation or tax normalization — are trimming the final conversion. For an analyst, the truest read of earning power is likely the operating margin, since net margin is further distorted by accelerating stock-based compensation (approximately 4.6% of revenue per the income statement analysis) and prior-year loss base effects.

Returns Recovering But Remain Capital-Shallow

ROIC swung from -4.7% in 2024Q4 to 7.2% in 2026Q3, per recent SEC filings, but this recovery is driven primarily by margin expansion rather than capital efficiency, with asset turnover improving only modestly from 0.20 to 0.30 over the same ten-quarter window.

A ROIC of 7.2% against a 3.91x current ratio implies that a large portion of Kiniksa's capital base is idle cash rather than revenue-generating invested capital, so the economic return on genuinely deployed assets is likely higher than the headline figure suggests. Conversely, the return profile is not yet compounding in a way that would justify premium pricing on a standalone basis; compared to the pre-2025 loss-making era, the improvement is real, but against historical pharma ROIC norms it remains modest. Investors should monitor whether KPL-404 commercialization can raise asset turnover structurally or whether the company remains a low-asset-intensity, cash-accumulating entity whose ROIC is diluted by its own balance sheet.

Inventory-Led Working Capital Cycle Lengthens

Kiniksa's cash conversion cycle has held in the 52-68 day range, with DIO at 62 days in 2026Q3 dwarfing DSO of 9 days and DPO of 6 days, according to reported balance sheets, indicating working capital intensity is concentrated almost entirely in biologic inventory holdings.

The 9-day DSO confirms a highly efficient specialty-distributor collection structure typical of high-touch orphan drug commercialization, where wholesalers pay quickly against predictable demand — this supports the earnings-quality observation that operating cash flow has consistently exceeded net income. However, the 62-day inventory position and near-zero DPO (Kiniksa pays suppliers essentially on receipt) mean the company funds almost the entire cycle from its own cash, which is comfortable at current scale but would tighten if channel inventory built ahead of a launch or payer disruption slowed sell-through. The CCC trending down from 68 days in 2024Q2 to 65 days alongside rising asset turnover (0.20 to 0.30) points to improving, though not exceptional, working capital discipline as the commercial engine scales.

Multiples Price in Platform Transition Premium

Kiniksa trades at a TTM P/E of 118.9 and forward P/E of 65.3, with EV/EBITDA of 84.3x and P/S of 10.0x, implying investors are pricing a multi-asset outcome rather than the current ARCALYST-driven earnings stream alone, based on current market pricing data.

The forward P/E compression from 118.9 to 65.3 reflects expected earnings growth off a small, recently positive base — a denominator effect rather than evidence of a cheap valuation on any absolute measure. At 10.0x sales and a P/FCF of 267.5x, the market is essentially paying for pipeline optionality (KPL-404, vixarelimab milestones) and potential strategic-buyer premium, consistent with the acquisition-target framing noted in the peer context. Given the Regeneron profit share structurally caps gross margin near 55%, the risk-reward at these multiples is asymmetric: any deceleration in ARCALYST new patient starts or KPL-404 differentiation failure could compress multiples materially, since there is little margin expansion left to support the growth narrative.

Only Profitable Name Commands Peer-Group Premium

Against a peer set of ARDX, PRAX, RCUS, IMVT, and CABA — all carrying negative ROE and mostly negative net margins — Kiniksa's 16.6% net margin and 0.01 D/E distinguish it fundamentally, yet its P/B of 12.4x far exceeds the peer range of 1.3-6.9x, per available peer data.

The profitability gap versus peers appears structural rather than temporary, as Kiniksa has already achieved commercial self-funding while comparables remain dependent on capital markets, meaning the divergence is unlikely to close through peer improvement alone. However, the P/B premium of roughly 2x the highest peer multiple (IMVT at 6.18x) is not obviously justified by ROE alone — at 6.9%, Kiniksa's ROE is positive but not yet at levels that typically command such a book-value multiple, so the premium must be attributed to growth expectations and pipeline optionality rather than current return generation. Sobi and Argenx, referenced as the true operational and valuation peers respectively, are not included in this data set, so this comparison should be treated as directional rather than conclusive for relative-value positioning.

P/E Misapplied to a Recently Profitable Single-Asset Biotech

The 118.9x trailing P/E is the ratio most commonly misapplied here, since it rests on a profit base that only turned positive in 2025Q1 and is further distorted by accelerating SBC and prior-year loss denominators, per Kiniksa's quarterly filings, making it analytically unreliable for this business model.

What the P/E obscures is the difference between accounting profitability achieved during a commercial ramp and durable earning power constrained by the Regeneron profit share — investors should instead anchor on EV/Sales or risk-adjusted pipeline value, since the gross margin ceiling means incremental revenue will not translate to margin expansion the way a normalized P/E assumes. A second commonly misapplied metric is the 3.91x current ratio, which reads as fortress liquidity but reflects an asset-light model with near-zero fixed capital and cash that, based on reported balance sheets, has already drawn down from $190.0M to $81.7M over two quarters; the more informative signal is the absence of any debt service requirement (D/E of 0.01), which removes refinancing risk independent of the headline ratio.

Download Financial Ratios Data

Includes 30+ ratios · 10 years · Updated daily

Consensus & Technical Research Suite
Open KNSA Terminal

KNSA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

KNSA — Frequently Asked Questions

Quick answers to the most common questions about buying KNSA stock.

What is Kiniksa Pharmaceuticals International, plc's P/E ratio?

Kiniksa Pharmaceuticals International, plc's current P/E ratio is 73.7x. The historical average is 49.5x. This places it at the 67th percentile of its historical range.

What is Kiniksa Pharmaceuticals International, plc's EV/EBITDA?

Kiniksa Pharmaceuticals International, plc's current EV/EBITDA is 53.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 58.2x.

What is Kiniksa Pharmaceuticals International, plc's ROE?

Kiniksa Pharmaceuticals International, plc's return on equity (ROE) is 11.7%. The historical average is -9.2%.

Is KNSA stock overvalued?

Based on historical data, Kiniksa Pharmaceuticals International, plc is trading at a P/E of 73.7x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Kiniksa Pharmaceuticals International, plc's profit margins?

Kiniksa Pharmaceuticals International, plc has 54.6% gross margin and 11.4% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does Kiniksa Pharmaceuticals International, plc have?

Kiniksa Pharmaceuticals International, plc's Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.